SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 26, 2005
---------------
INTERPHARM HOLDINGS, INC.
(Exact name of Registrant as specified in charter)
Delaware 0-22710 13-3673965
(State or other jurisdic- (Commission (IRS Employer
tion of incorporation) File Number) Identification No.)
75 Adams Avenue, Hauppauge, New York 11788
-------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (631) 952-0214
--------------
NOT APPLICABLE
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|_| Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers
On May 26, 2005, Surinder Rametra, Director of Business Development for
Interpharm Holdings, Inc. (the "Company"), resigned this executive officer
position. Mr. Rametra will continue as an employee of the Company as Facilities
Manager for the Company's second location in Yaphank, New York.
Mr. Rametra's resignation is not a result of any disagreement with the
Company on any matter, including any matter related to the operations, policies
or practices of the Company.
The Company has not appointed any person to fill in the vacancy created by
the resignation of Mr. Rametra.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
INTERPHARM HOLDINGS, INC.
May 27, 2005 By: /s/ George Aronson
-----------------------------------
George Aronson
Chief Financial Officer